|
|
|
Stem Cell Related Patent Number US5656724
| Title: | Chemokine-like proteins and methods of use | | Inventors: | Daly, Thomas J.; Framingham, MA, USA
LaRosa, Gregory J.; Boston, MA, USA | | Summary: | Described herein are chemokine-like proteins with active domains from different chemokines, methods and uses thereof. The invention relates to novel chemokine-like proteins that include two or more such active domains which represent regions of several contiguous amino acids that are necessary for the ability of chemokines to suppress the proliferation of actively dividing myeloid cells such as myeloid progenitor, myeloid stem and leukemic cells. Claims of the invention include higher myelosuppressive activity than that occurring in wild-type chemokines, as well as modified activities which exhibit high myelosuppressivity. . Amino acid sequences reveal a wild-type interleukin-8 (IL-8) having four cysteine residues, properties of which are disclosed herein. Therapeutic applications are included for the treatment of a wide variety of diseases, including hyperproliferative myeloid disease, chronic myelogenous leukemia, polycythemia vera, hypermegakaryocytopoietic disorder, and for treatment in cases requiring the protection of myeloid progenitor cells from chemotherapeutic agents and radiation therapy. | | Abstract: | The invention relates to novel chemokine-like proteins that include two or more newly discovered active domains from different chemokines. Active domains are regions of several contiguous amino acids that are necessary for chemokines' ability to suppress the proliferation of actively dividing myeloid cells, e.g., myeloid progenitor cells, myeloid stem cells, and leukemic cells. The new chemokine-like proteins provide higher myelosuppressive activity than naturally occurring, wild-type chemokines. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5656724 | | Application Number: | US1994000330163 | | Date Filed: | 26/10/1994 | | Date Published: | 12/08/1997 | | Assignee: | Repligen Corporation, Cambridge, MA, USA |
|
|
